WALVAX BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.33 CNY | +3.54% |
|
+2.43% | -39.05% |
| 04-26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
| 04-25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
| Sales 2024 * | 4.13B 570M 45.67B | Sales 2025 * | 5.36B 740M 59.29B | Capitalization | 22.92B 3.16B 253B |
|---|---|---|---|---|---|
| Net income 2024 * | 781M 108M 8.63B | Net income 2025 * | 1.12B 155M 12.39B | EV / Sales 2024 * | 4.54 x |
| Net cash position 2024 * | 4.17B 575M 46.08B | Net cash position 2025 * | 4.77B 658M 52.68B | EV / Sales 2025 * | 3.38 x |
| P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
20.6
x | Employees | 2,388 |
| Yield 2024 * |
0.7% | Yield 2025 * |
0.84% | Free-Float | 27.42% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +3.54% | ||
| 1 week | +2.43% | ||
| Current month | -6.83% | ||
| 1 month | -10.77% | ||
| 3 months | -22.54% | ||
| 6 months | -34.51% | ||
| Current year | -39.05% |
1 week
13.13
14.47
1 month
13.1316.12
Current year
13.1323.66
1 year
13.1332.23
3 years
13.1396.73
5 years
13.1396.73
10 years
5.0596.73
| Managers | Title | Age | Since |
|---|---|---|---|
Run Sheng Jiang
PSD | President | 67 | 21/06/16 |
Hua Zhou
DFI | Director of Finance/CFO | 57 | 22/06/14 |
Shao zhong Dong
BRD | Director/Board Member | 56 | 26/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhen Huang
BRD | Director/Board Member | 61 | 31/12/02 |
Yun Chun Li
CHM | Chairman | 62 | 22/06/09 |
Jin Yu Zhu
BRD | Director/Board Member | 57 | 22/06/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 14.33 | +3.54% | 24,848,250 |
| 25/04/24 | 13.84 | -2.12% | 26,536,100 |
| 24/04/24 | 14.14 | -0.77% | 13,425,930 |
| 23/04/24 | 14.25 | -0.28% | 14,354,610 |
| 22/04/24 | 14.29 | +2.14% | 14,827,800 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.
Sector
Pharmaceuticals
Calendar
25/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
14.33
CNY
Average target price
20
CNY
Spread / Average Target
+39.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.05% | 3.16B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300142 Stock
